Skip to main content
Retour
Watch Compare

Mosaic ImmunoEngineering Inc.

Qualité des données : 83%
CPMV
OTC Manufacturing Chemicals
0,70 €
▼ 0,05 € (-6,71%)
Cap. Boursière: 5,40 M
Prix
0,75 €
Cap. Boursière
5,40 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -103 975,0

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio0,01
Interest Coverage-58,96

Valorisation

PE (TTM)
-8,03
En dessous de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1385 pairs)
Métrique Action Médiane du Secteur
P/E -8,0 -1,5
P/B — 1,6
ROE % — -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Objectif de Cours des Analystes

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Aucune estimation prévisionnelle disponible

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -671 753,0
ROE N/A ROA -1188,97%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -103 975,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,01
Interest Coverage -58,96 Asset Turnover N/A
Working Capital -5,86 M Tangible Book Value -7,31 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -8,03 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1,93%
Market Cap 5,40 M Enterprise Value 5,36 M
Per Share
EPS (Diluted TTM) -0,09 Revenue / Share N/A
FCF / Share -0,01 OCF / Share -0,01
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 15,48%
SBC-Adj. FCF -103 975 Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -921 983,0 -1,01 M -2,38 M -3,68 M -842 243,0
EPS (Diluted) -0,13 -0,14 -0,33 -0,55 -1,12
Gross Profit — — — — —
Operating Income -879 655,0 -1,40 M -2,63 M — —
EBITDA — — — — —
R&D Expenses 183 867,0 435 449,0 1,05 M 1,46 M 342 727,0
SG&A Expenses — — — — 996 019,0
D&A — — — — —
Interest Expense 6 954,0 — — — —
Income Tax 2 400,0 2 400,0 2 400,0 2 400,0 1 600,0

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 141 611,0 179 533,0 261 277,0 269 494,0 457 802,0
Total Liabilities 6,93 M 6,05 M 5,15 M 3,07 M 880 343,0
Shareholders' Equity -6,79 M -5,87 M -4,88 M -2,80 M -422 541,0
Total Debt — — — — —
Cash & Equivalents 115 019,0 156 178,0 220 645,0 226 142,0 352 738,0
Current Assets 141 611,0 179 533,0 261 277,0 269 494,0 457 802,0
Current Liabilities 5,54 M 4,73 M 3,92 M 2,33 M 880 343,0